To further investigate the impact of CD103 expression on tumor-infiltrating CD3+ CD+ T cells, we stimulated tumor-infiltrating CD+ T cells through anti-CD3, anti-CD28, PMA and Ionomycin or anti-PD-1 in vitro for 12 h (Fig. 6a, b). The gene discussed is CD28; the disease is neoplasm.